CDK2 and triple-negative breast carcinoma: Molecular docking demonstrated the strong binding relation between the main active compounds of KLT injection (Isoarborinol and Sitosterol alpha1) and the targets (CDK1, CDK2, and CHEK1) in triple-negative breast cancer [5].